Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28


Male Burmese pythons follow female scent trails and show sex-specific behaviors.

Richard SA, Tillman EA, Humphrey JS, Avery ML, Parker MR.

Integr Zool. 2019 Sep;14(5):460-469. doi: 10.1111/1749-4877.12376. Epub 2019 Jun 26.


Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.

Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators.

Lancet Oncol. 2018 Sep;19(9):1192-1204. doi: 10.1016/S1470-2045(18)30379-6. Epub 2018 Aug 9. Erratum in: Lancet Oncol. 2018 Nov;19(11):e581.


Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia.

Ruppe MD, Zhang X, Imel EA, Weber TJ, Klausner MA, Ito T, Vergeire M, Humphrey JS, Glorieux FH, Portale AA, Insogna K, Peacock M, Carpenter TO.

Bone Rep. 2016 May 13;5:158-162. doi: 10.1016/j.bonr.2016.05.004. eCollection 2016 Dec.


Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23.

Imel EA, Zhang X, Ruppe MD, Weber TJ, Klausner MA, Ito T, Vergeire M, Humphrey JS, Glorieux FH, Portale AA, Insogna K, Peacock M, Carpenter TO.

J Clin Endocrinol Metab. 2015 Jul;100(7):2565-73. doi: 10.1210/jc.2015-1551. Epub 2015 Apr 28. Erratum in: J Clin Endocrinol Metab. 2017 Jan 1;102(1):336.


Detecting an elusive invasive species: a diagnostic PCR to detect Burmese python in Florida waters and an assessment of persistence of environmental DNA.

Piaggio AJ, Engeman RM, Hopken MW, Humphrey JS, Keacher KL, Bruce WE, Avery ML.

Mol Ecol Resour. 2014 Mar;14(2):374-80. doi: 10.1111/1755-0998.12180. Epub 2013 Nov 5.


The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.

Seymour L, Ivy SP, Sargent D, Spriggs D, Baker L, Rubinstein L, Ratain MJ, Le Blanc M, Stewart D, Crowley J, Groshen S, Humphrey JS, West P, Berry D.

Clin Cancer Res. 2010 Mar 15;16(6):1764-9. doi: 10.1158/1078-0432.CCR-09-3287. Epub 2010 Mar 9.


GCP data quality for early clinical development.

Rock EP, Molloy VJ, Humphrey JS.

Clin Cancer Res. 2010 Mar 15;16(6):1756-63. doi: 10.1158/1078-0432.CCR-09-3267. Epub 2010 Mar 9.


Effect of the Veterans Affairs Medical System on plastic surgery residency training.

Ravin AG, Gottlieb NB, Wang HT, Meade RA, Humphrey JS, Schwarz KW, Levin LS, Tyler DS, Erdmann D.

Plast Reconstr Surg. 2006 Feb;117(2):656-60.


Sural flap delay procedure: a preliminary report.

Erdmann D, Gottlieb N, Humphrey JS, Le TC, Bruno W, Levin LS.

Ann Plast Surg. 2005 May;54(5):562-5.


Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18.

Leighl NB, Paz-Ares L, Douillard JY, Peschel C, Arnold A, Depierre A, Santoro A, Betticher DC, Gatzemeier U, Jassem J, Crawford J, Tu D, Bezjak A, Humphrey JS, Voi M, Galbraith S, Hann K, Seymour L, Shepherd FA.

J Clin Oncol. 2005 Apr 20;23(12):2831-9.


Yeast-based assays for detection and characterization of mutations in BRCA1.

Monteiro AN, Humphrey JS.

Breast Dis. 1998 Apr;10(1-2):61-70.


A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer.

Rizvi NA, Humphrey JS, Ness EA, Johnson MD, Gupta E, Williams K, Daly DJ, Sonnichsen D, Conway D, Marshall J, Hurwitz H.

Clin Cancer Res. 2004 Mar 15;10(6):1963-70.


Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor.

Lockhart AC, Braun RD, Yu D, Ross JR, Dewhirst MW, Humphrey JS, Thompson S, Williams KM, Klitzman B, Yuan F, Grichnik JM, Proia AD, Conway DA, Hurwitz HI.

Clin Cancer Res. 2003 Feb;9(2):586-93.


Phase I clinical trial design in cancer drug development.

Eisenhauer EA, O'Dwyer PJ, Christian M, Humphrey JS.

J Clin Oncol. 2000 Feb;18(3):684-92.


Constitutional von Hippel-Lindau (VHL) gene deletions detected in VHL families by fluorescence in situ hybridization.

Pack SD, Zbar B, Pak E, Ault DO, Humphrey JS, Pham T, Hurley K, Weil RJ, Park WS, Kuzmin I, Stolle C, Glenn G, Liotta LA, Lerman MI, Klausner RD, Linehan WM, Zhuang Z.

Cancer Res. 1999 Nov 1;59(21):5560-4.


The independent effects of left ventricular ejection fraction on short-term outcomes and resource utilization following hospitalization for heart failure.

Harjai KJ, Nunez E, Turgut T, Shah MP, Humphrey JS, Newman J, Cheirif J, Smart FW, Ventura HO.

Clin Cardiol. 1999 Mar;22(3):184-90.


Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene.

Stolle C, Glenn G, Zbar B, Humphrey JS, Choyke P, Walther M, Pack S, Hurley K, Andrey C, Klausner R, Linehan WM.

Hum Mutat. 1998;12(6):417-23.


Pharmacokinetics of a degradable drug delivery system in bone.

Humphrey JS, Mehta S, Seaber AV, Vail TP.

Clin Orthop Relat Res. 1998 Apr;(349):218-24.


Human BRCA1 inhibits growth in yeast: potential use in diagnostic testing.

Humphrey JS, Salim A, Erdos MR, Collins FS, Brody LC, Klausner RD.

Proc Natl Acad Sci U S A. 1997 May 27;94(11):5820-5.


Gentamicin distribution from a collagen carrier.

Mehta S, Humphrey JS, Schenkman DI, Seaber AV, Vail TP.

J Orthop Res. 1996 Sep;14(5):749-54.


Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma.

Gnarra JR, Duan DR, Weng Y, Humphrey JS, Chen DY, Lee S, Pause A, Dudley CF, Latif F, Kuzmin I, Schmidt L, Duh FM, Stackhouse T, Chen F, Kishida T, Wei MH, Lerman MI, Zbar B, Klausner RD, Linehan WM.

Biochim Biophys Acta. 1996 Mar 18;1242(3):201-10. Review. No abstract available.


Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density.

Lee S, Chen DY, Humphrey JS, Gnarra JR, Linehan WM, Klausner RD.

Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):1770-5.


Von Hippel-Lindau syndrome: hereditary cancer arising from inherited mutations of the VHL tumor suppressor gene.

Humphrey JS, Klausner RD, Linehan WM.

Cancer Treat Res. 1996;88:13-39. Review. No abstract available.


Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations.

Duan DR, Humphrey JS, Chen DY, Weng Y, Sukegawa J, Lee S, Gnarra JR, Linehan WM, Klausner RD.

Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6459-63.


TGN38 recycles basolaterally in polarized Madin-Darby canine kidney cells.

Rajasekaran AK, Humphrey JS, Wagner M, Miesenböck G, Le Bivic A, Bonifacino JS, Rodriguez-Boulan E.

Mol Biol Cell. 1994 Oct;5(10):1093-103.


Localization of TGN38 to the trans-Golgi network: involvement of a cytoplasmic tyrosine-containing sequence.

Humphrey JS, Peters PJ, Yuan LC, Bonifacino JS.

J Cell Biol. 1993 Mar;120(5):1123-35.

Supplemental Content

Loading ...
Support Center